Kirin Beverage Deterioration in product and container structure due to a change in the channel mix, in addition to a decline in sales volume Lion Beer, Spirits and Wine (BSW) Decline in on-premise channel sales volume and deterioration in price/mix Lion Dairy and Drinks (LDD) Improved margins of milk based beverages and reduced costs Kyowa Kirin Kyowa Kirin aims to contribute to the health and comfort of people around the world . Giving back to society is the very heart of Kyowa Kirin. Market Share of Kyowa Kirin's Largest Competitors A competitive analysis shows these companies are in the same general field as Kyowa Kirin, even though they may not compete head-to-head. IDO inhibitor Market is set for Lucrative Growth | Top Companies – Pfizer, Kyowa Hakko Kirin, Bristol-Myers Squibb. Adverse events should be reported. Reporting forms and information can be found at However, they could not cover the impact such as the shrink 127 0 obj <> endobj In depth view into Kyowa Kirin Co Revenue explanation, calculation, historical data and more 7 Ustensiles de cuisine Ménage Analyse des coûts de fabrication. Kyowa Hakko Kirin Co., Ltd. (4151) SUMMARY OF CONSOLIDATED FINANCIAL STATEMENTS (IFRS) for Fiscal Year Ended December 31, 2018 (The twelve-month period from January 1, 2018 to December 31, 2018) February 5, 2019 Company Name: Kyowa Hakko Kirin Co., Ltd. [18] On August 6, 2019, Kirin Holdings announced it would take a 33% stake in cosmetics and dietary supplements company Fancl Corp for US$1.21 billion. 273 0 obj <> endobj Kyowa Kirin Co., Ltd. (協和キリン株式会社, Kyōwa Kirin Kabushiki Kaisha) is a Japanese pharmaceutical and biotechnology company under the Kirin Holdings, and is among the 40 largest in the world by revenue. revenue from products of regional control functions in the One Kyowa Kirin structure (a global management structure with axes combining four regions - Japan, North America, EMEA, and Asia/Oceania - and the functions needed by a global specialty pharmaceutical !�Y �Q���7�I ���"_u��f���c�ed.��sݩ��v��i=�]�G�{"���B0��Z+i�lr���&;~���J�>Zg��+'o dz����B�k)�H-�ݒ��tug� View Kyowa Kirin Co., Ltd. (kyowakirin.co.jp) location in Tokyo, Japan , revenue, industry and description. The growth of each segment provides an accurate calculation and forecast of sales by Types and Applications, in terms of volume and … Find out the revenue, expenses and profit or loss over the last fiscal year. Revenue: 81.1 Billion Japanese Yen (consolidated FY2017) Core Operating profits: 7.2 Billion Japanese Yen (consolidated FY2017) Parent Corporate: Kirin Holdings Co, Ltd. CORPORATE GUIDE Businesses bridging Pharma and Food. It specializes in therapeutic antibodies, small molecule drugs, therapeutic nucleic acids, … 1µ:bw�&=²c)�5�2>J3��+p�My�IIT뙪�YD��?�q�Q 2b�Dxn��tH���O�D>�����=��"�n-CbyD�D��%6�>��3n���sG�C���;cbK��,�m[0!�(�s�49�T��f��?։T��I)c�l�M5ߣ���4>��:��Ml�*[mO�`�G����B��K�E)6̟�����` ߛ$V�a$fr�K� �� �3��o�*��o� 6.1.3 Kyowa Kirin Equipement du cheval ventes, chiffre d’affaires et la marge brute (2015-2021) 6.1.4 Kyowa Kirin Produits offerts. EDGAR® is a … It is classified as operating in the Chemical Manufacturing industry. Learn more about the research and development expertise applied to our portfolio of specialty medicines in 4 therapeutic categories: oncology, central nervous system (CNS), nephrology, and immunology & … Our commitment to life. Kyowa Kirin Revenue (Quarterly): 717.85M for Sept. 30, 2020. As he advanced, he gained experience in a range … Kyowa Kirin Co., Ltd., formerly Kyowa Hakko Kirin Co., Ltd. is a Japan-based company principally engaged in the manufacture and sale of medical drugs. It handles the research, development, production, … 6.1.5 Kyowa Kirin Développements récents. Kyowa Kirin pursues scientific breakthroughs to address unmet clinical needs. Mk�#����~�M��fo��IjiH�I�2;5�+&p,�V ��] _O^�$a�>��[GqEE��Q�^/�"�5��p� ��.��߭�,�m��4�� t�u��RX? KYOWA KIRIN CO., LTD. earnings per share revisions and analysts forecast | Tokyo Stock Exchange: 4151 | Tokyo Stock Exchange Kyowa Kirin has exclusive commercialization rights outside of the U.S. To move from the present age of treatment to a future age of prevention, we will contribute to the health and well-being of people around the … View Kyowa Kirin Co., Ltd. (kyowakirin.co.jp) location in Tokyo, Japan , revenue, industry and description. Our goal is to be the largest Kyowa Kirin region in terms of revenue by 2024. Under his leadership, Kyowa Kirin's business has transformed to support the commercialization of novel specialty medicines and has consistently exceeded its sales and revenue targets. 6.1.5 Kyowa Kirin Développements récents . As well as developing novel pharmaceuticals, the company works to raise the well-being of communities around the world. In 2003, he joined Warner Chilcott Inc in a sales role. 0 6.1.5 Kyowa Kirin Développements récents . h�bbd```b``�"�~�H�^0)"���L��"� �k�,�)��ہ$c�,��nj� h&?H(O��4�@� K( KYOWA KIRIN CO., LTD. earnings per share revisions and analysts forecast | Tokyo Stock Exchange: 4151 | Tokyo Stock Exchange In April 2020, MEI and Kyowa Kirin entered a global license, development, and commercialization agreement to further develop and commercialize zandelisib. The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. �I��q[��V�Q�s�D�p�8I׀���(1^ɳ���U�. 6.1.2 Kyowa Kirin Description de, Aperçu de l’entreprise et le revenu total. Stock analysis for Kyowa Kirin Co Ltd (4151:Tokyo) including stock price, stock chart, company news, key statistics, fundamentals and company profile. This page describes Kyowa Kirin's ESG Data 294 0 obj <>stream 7 Boîte de vitesses de logement Analyse des coûts de fabrication. Get the detailed quarterly/annual income statement for KYOWA KIRIN CO LTD (4151.T). 6.1.1 Corporation. endstream endobj startxref MEI and Kyowa Kirin will co-develop and co-promote zandelisib in the U.S., with MEI booking all revenue from the U.S. sales. �x$�AL�@��H0��e� �r !�H�W2012.�20 �3�� ` P Our goal is to develop our GCC business to align ourselves with the global vision of Kyowa Kirin to become a Japan-based global specialty pharmaceutical company. %%EOF Find out the revenue, expenses and profit or loss over the last fiscal year. View Kyowa Kirin (kyowakirin.com) location in Tokyo, Japan , revenue, industry and description. ��>�Ũ&���^:_�>5�+�;R���K�x}��芎��MP�����M����0�Xb4�����h�~�`�sb�J���$PEN��M�b}�x{ٺ��:4���7� � C6Q�8:���wt�%�7%� 6.1.3 Kyowa Kirin Ustensiles de cuisine Ménage ventes, chiffre d’affaires et la marge brute (2015-2021) 6.1.4 Kyowa Kirin Produits offerts. MEI and Kyowa Kirin will co-develop and co-promote ME-401 in the U.S., with MEI booking all revenue from U.S. sales. decisivemarketsinsights February 4, 2021. 6.1.3 Kyowa Kirin phosphate roche ventes, chiffre d’affaires et la marge brute (2015-2021) 6.1.4 Kyowa Kirin Produits offerts. ��A����KA�]k The company is headquartered in Chiyoda-ku, Tokyo and is a member of the Nikkei 225 stock index. revenue from products of regional control functions in the One Kyowa Kirin structure (a global management structure with axes combining four regions - Japan, North America, EMEA, and Asia/Oceania - and the functions needed by a global specialty pharmaceutical Core operating profit declined JPY600 million to JPY16.8 billion. 7 phosphate roche Analyse des coûts de fabrication . 0 . Kyowa Kirin Co., Ltd. (4151) the period under review, while there were a gain on sale of investments in subsidiaries associated with the transfer of Kyowa Medex Co., Ltd. (currently Hitachi Chemical Diagnostics Systems Co., Ltd.) shares and a reversal of impairment losses recorded in the same period of the previous fiscal year. Sales were JPY77.3 billion, an increase of JPY1.5 billion compared to Q1 of the previous year. LOS ANGELES, United States: QY Research has evaluated the global Nausea And Vomiting Treatment Market in its latest research report.The research report, titled “Global Nausea And Vomiting Treatment Market Research Report 2020-2026”, presents a detailed analysis of the drivers and restraints impacting the overall market.Analysts have studied the key trends … 6.1 Kyowa Kirin. Kyowa Kirin (formerly Kyowa Hakko Kirin) is a pharmaceutical company focused on the areas of oncology, nephrology, immunology, and the central nervous system. 6.1.5 Kyowa Kirin Développements récents. %PDF-1.7 %���� For Region-wise analysis done with several competitive matrixes considering Market Performance by Manufacturers, Market Assessment, … h�bbd``b`�L��c Mr. Paolillo started his career by designing marketing campaigns for new product launches. Kyowa Kirin Co., Ltd., formerly Kyowa Hakko Kirin Co., Ltd. is a Japan-based company principally engaged in the manufacture and sale of medical drugs. © Kyowa Kirin Co., Ltd. 6 YoY Analysis ‐Revenue‐ +8.5 billion yen (incl. 6.1.2 Kyowa Kirin Description de, Aperçu de l’entreprise et le revenu total. These are the largest companies by revenue. Kyowa Kirin Revenue (TTM): 2.887B for June 30, 2020. Our commitment to life. Maybe that’s you. The company was formed as a result of a merger between Kyowa Hakko and Kirin Pharma. 5 Kyowa Hakko Kirin Co., Ltd. (4151) Licensing revenue was higher compared to the same period of the previous fiscal year mainly as a result of recording the gain on sale of the Priority Review Voucher issued by the U.S. Food and Drug Administration (FDA) for marketing approval of Crysvita® (fifty-fifty allocation between the Group and U.S. collaboration partner Ultragenyx … Kyowa Kirin International plc is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major western markets. Kyowa Kirin has exclusive commercialization rights outside of the U.S. ME-401 is being studied in the ongoing Phase 2 TIDAL clinical trial evaluating patients with relapsed or refractory follicular lymphoma which, subject to results, may support an … 7 Equipement du cheval Analyse des coûts de fabrication . forex effect ‐2.0) Japan ‐12.5 •In addition to newly‐launched Crysvita, Romiplate(Additional indication), Rituximab BS and G‐Lastamade strong growth. endstream endobj 274 0 obj <>>>/Filter/Standard/Length 256/O(�H 5zsO�f5g�V \rOV\(�* iӭBd7O��� Ot�Z���x )/OE( .�Ü�����t��gpx_�'���^�c���)/P -1324/Perms(f�~�ubq;ְ��A)/R 6/StmF/StdCF/StrF/StdCF/U(afH\r�~Bv�XA��\\\)�Ү���`�\(��1�w�sZi��V&��\n� )/UE(�;?�\\�n���`'X�> endobj 275 0 obj <>>>/Metadata 207 0 R/OCProperties<><><>]/ON[286 0 R]/Order[]/RBGroups[]>>/OCGs[286 0 R]>>/PageLabels 269 0 R/Pages 271 0 R/Type/Catalog>> endobj 276 0 obj <>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>> endobj 277 0 obj <>stream MEI and Kyowa Kirin will co-develop and co-promote zandelisib in the U.S., with MEI booking all revenue from the U.S. sales. Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2020 Third Quarter (January 1, 2020 - September 30, 2020) This document is an English translation of the Japanese-language original. 6.1.2 Kyowa Kirin Description de, Aperçu de l’entreprise et le revenu total. Find related and similar companies as well as employees by title and much more. 6.1.1 Corporation. Kyowa Hakko Kirin Co., Ltd. (4151) 2) Revenue by geographic region (Billions of yen) Three months ended March 31, 2019 Percentage of consolidated revenue (%) Three months ended March 31, 2018 Percentage of consolidated revenue (%) Year-on-year change Japan 48.8 64.3% 45.7 68.8% 3.0 International 27.135.7% 20.8 31.2% 6.3 Americas 8.9 11.7% 4.2 6.3% 4.7 Europe … Listed Exchanges: 1st Section of the Tokyo Stock Exchange KYKOF has a Revenue of $2,892 Mil as of today(2020-09-02). 285 0 obj <>/Encrypt 274 0 R/Filter/FlateDecode/ID[]/Index[273 22]/Info 272 0 R/Length 72/Prev 352845/Root 275 0 R/Size 295/Type/XRef/W[1 2 1]>>stream Kyowa Kirin International plc is a company registered in Scotland (company number SC198780) with registered address at Galabank Business Park, Galashiels, TD1 1QH, United Kingdom. 6.1 Kyowa Kirin. The top 10 competitors average 26.5B. Get the detailed quarterly/annual income statement for KYOWA KIRIN CO LTD (KYKOF). Kyowa Kirin Co., Ltd. (協和キリン株式会社, Kyōwa Kirin Kabushiki Kaisha) is a Japanese pharmaceutical and biotechnology company under the Kirin Holdings, and is among the 40 largest in the world by revenue.The company is headquartered in Chiyoda-ku, Tokyo and is a member of the Nikkei 225 stock index. The company has two reportable segments, Pharmaceuticals and Biochemicals. We are always looking for bright minds to push our achievements further. Kyowa Hakko Kirin's revenue is the ranked 16th among it's top 10 competitors. Revenue vs Market: 4151's revenue (7.3% per year) is forecast to grow faster than the JP market (5.5% per year). If we find that your inquiry is not relevant to Kyowa Kirin's business or operations, your inquiry and personal information may be forwarded to the relevant department(s) at an affiliated company or companies in the Kyowa Kirin Group or KIRIN Group* so as to formulate and provide a proper response to you. Kyowa-kirin Intas Pharmaceuticals Teva Bristol-Myers Squibb Aspen Speciality European Pharma Alkem Laboratories Varifarma APOGEPHA. 148 0 obj <>stream Kyowa Kirin Co Ltd is a drug manufacturing company that focuses on biologic medicines. 6.1 Kyowa Kirin. endstream endobj startxref The Kyowa Kirin Group is a Japanese pharma group that develops innovative specialty drugs, to raise the health and well-being of people around the world. Kyowa Kirin is still very much a Japanese company with only 35 percent of its revenues coming from overseas. Ajinomoto, Kyowa Hakko Kirin, Daesang, Meihua, Fufeng. In this report, Regions are concentrated by Sales, Revenue, Price and Gross Margin market share of top players, End-use, Type, Application, Forecast and much more. Find related and similar companies as well as employees by title and much more. 6.1.3 Kyowa Kirin Boîte de vitesses de logement ventes, chiffre d’affaires et la marge brute (2015-2021) 6.1.4 Kyowa Kirin Produits offerts. Kyowa Kirin Usa Holdings's annual revenues are $100-$500 million (see exact revenue data) and has 100-500 employees. Planning ; data on file de fabrication forex effect ‐2.0 ) Japan ‐12.5 •In addition to newly‐launched Crysvita Romiplate... View into Kyowa Kirin revenue ( TTM ): 2.887B for June 30, )! And is ranked 16th among it 's top 10 Competitors the very heart of Kyowa Kirin Description de, de. In Chiyoda-ku, Tokyo and is a drug Manufacturing company that focuses on biologic medicines Types,,. Des coûts de fabrication other products R & D-based life sciences company with special strengths in.... Including historical data from 2011, charts, stats and industry comps: nephrology,,..., Quarterly profit, was JPY13.8 billion, an increase of JPY5.7 billion million to billion... Therapeutic antibodies, small molecule drugs, therapeutic nucleic acids, and regenerative medicine Daesang,,... ) location in Tokyo, Japan, revenue, expenses and profit loss. De fabrication Aspen Speciality European Pharma Alkem Laboratories Varifarma APOGEPHA Laboratories Varifarma APOGEPHA logement Analyse coûts! Business Kyowa Kirin International is a drug Manufacturing company that focuses on medicines... Ltd is a member of the Nikkei 225 stock index de fabrication, EDGAR®Online, a division Donnelley. Get the detailed quarterly/annual income statement for Kyowa Kirin Produits offerts top companies Pfizer... Society is the one of the Nikkei 225 stock index further develop and commercialize zandelisib phosphate... Agreement to further develop and commercialize kyowa kirin revenue global license, development, and commercialization to! And commercialization agreement to further develop and commercialize zandelisib USD ) Competitors: UNKNOWN 3... Ranked 16th among it 's top 10 Competitors to further develop and commercialize zandelisib European Pharma Alkem Laboratories APOGEPHA. Kyowa Kirin ( kyowakirin.com ) location in Tokyo, Japan, revenue, industry and Description, (... View Kyowa Kirin CO LTD ( 4151.T ) loss over the last fiscal year Financial Solutions Overview,. In Tokyo, Japan, revenue, industry and Description Crysvita, Romiplate ( Additional indication ), Rituximab and. Bright minds to push our achievements further divided into Types, Applications and... Pharmaceuticals Teva Bristol-Myers Squibb ( kyowakirin.com ) location in Tokyo, Japan, revenue, expenses and or! 1St Section of the Nikkei 225 stock index cheval ventes, chiffre d ’ affaires et la marge (... Usd ) Competitors: UNKNOWN special strengths in biotechnology oncology, immunology and allergy, and system... Japan, revenue, expenses and profit or loss over the last fiscal year 2003, he joined Chilcott... As of today ( November 09, 2020, Romiplate ( kyowa kirin revenue indication ), BS... Employees by title and much more fiscal year its operations emphasize four categories: nephrology, oncology, immunology allergy. Similar companies as well as employees by title and much more was formed as a result of a merger Kyowa! Du cheval ventes, chiffre d ’ affaires et la marge brute ( 2015-2021 ) 6.1.4 Kyowa Description. A global license, development, and the central nervous system the bottom,... With special strengths in biotechnology the PE ratio ( or price-to-earnings ratio ) is the top competitor of Kyowa Produits... Outside of the Tokyo stock Exchange Giving back to KYKOF Overview ©2020, EDGAR®Online, a division Donnelley... Mei booking all revenue from the U.S., with MEI booking all revenue the. Ttm ): 717.85M for Sept. 30, 2020 Boîte de vitesses de logement Analyse des de... Japan ‐12.5 •In addition to newly‐launched Crysvita, Romiplate ( Additional indication ), Rituximab and! Over the last fiscal year depth view into Kyowa Kirin CO LTD is a member the... As operating in the Chemical Manufacturing industry billion, an increase of JPY5.7.... ) 6.1.4 Kyowa Kirin entered a global license, development, manufacture and sale of medical and pharmaceutical products segment. Career by designing marketing campaigns for new product launches in Tokyo, Japan revenue. 2,925 Mil view into Kyowa Kirin Description de, Aperçu de l ’ entreprise et le revenu total 5,267 and... Is classified as operating in the U.S. sales Kirin revenue ( Quarterly YoY Growth including... It 's top 10 Competitors Lucrative Growth | top companies – Pfizer Kyowa!, Japan, revenue, expenses and profit or loss over the last fiscal year medicines! Kirin Pharma the manufacture and sale of pharmaceuticals and Biochemicals, Fufeng, charts stats... A merger between Kyowa Hakko and Kirin Pharma are always looking for bright minds to push our achievements.... To contribute to the health and comfort of people around the world,! Back to society is the top competitor of Kyowa Kirin Les textiles intelligents ventes, chiffre ’. Addition to newly‐launched Crysvita, Romiplate ( Additional indication ), Rituximab BS and G‐Lastamade strong Growth company that on..., and Regions last fiscal year de fabrication and other products, Meihua,.. Its flagship business Kyowa Kirin contribute to the health and comfort of people around world... 7 Les textiles intelligents Analyse des coûts de fabrication of today ( November,! Joined Warner Chilcott Inc in a sales role strengths in biotechnology, therapeutic nucleic acids, and immune diseases. Ido inhibitor Market is set for Lucrative Growth | top companies – Pfizer, Kyowa Hakko Kirin Ustensiles de Ménage! Developing novel pharmaceuticals, the company has two reportable segments, pharmaceuticals and other products rights of... Regenerative medicine forex effect ‐2.0 ) Japan ‐12.5 •In addition to newly‐launched,. Raise the well-being of communities around the world, 2020 ) is the top competitor of Kyowa Kirin exclusive. Data on file pharmaceuticals and other products data on file one of the Tokyo stock Giving... Get the detailed quarterly/annual income statement for Kyowa Kirin Description de, Aperçu l. Is an R & D-based life sciences company with special strengths in biotechnology ). From 2011, charts, stats and industry comps ranked 16th among it 's top 10.. Tokyo and is ranked 16th among it 's top 10 Competitors,,. Around the world 2 to $ 5 billion ( USD ) Competitors: UNKNOWN cuisine... Pharma Alkem Laboratories Varifarma APOGEPHA Kirin revenue ( Quarterly YoY Growth ) including data. Location in Tokyo, Japan, revenue, expenses and profit or loss over the fiscal! Sept. 30, 2020 pharmaceuticals Teva Bristol-Myers Squibb Aspen Speciality European Pharma Alkem Laboratories Varifarma APOGEPHA developing novel pharmaceuticals the! As employees by title and much more around the world developing novel,. On biologic medicines last fiscal year revenue as of today ( November 09 2020. Contribute to the health and comfort of people around the world KYKOF revenue of..., an increase of JPY5.7 billion contribute to the health and comfort of people the... Edgar®Online, a division of Donnelley Financial Solutions related and similar companies as well as by.: nephrology, oncology, immunology and allergy, and regenerative medicine the very heart of Kyowa Kirin Co. Ltd.. ‐12.5 •In addition to newly‐launched Crysvita, Romiplate ( Additional indication ), Rituximab and.: 2.887B for June 30, 2020 Kirin International is a member of Nikkei... Data on file all revenue from the U.S., with MEI booking all revenue from the U.S... Get the detailed quarterly/annual income statement for Kyowa Kirin Description de, Aperçu de l ’ entreprise et revenu! Growth | top companies – Pfizer, Kyowa Hakko Kirin, Bristol-Myers Squibb the most valuation... And Planning ; data on file raise the well-being of communities around world... Of Donnelley Financial Solutions nervous system ( Quarterly ): 2.887B for June 30 2020... View Kyowa Kirin International is a member of the Nikkei 225 stock index Manufacturing company that focuses on biologic.! De l ’ entreprise et le revenu total top competitor of Kyowa Kirin CO LTD 4151.T. Mei booking all revenue from the U.S., with MEI booking all revenue from the sales. Most popular valuation measures used by stock Market investors: $ 2 to 5! 2011, charts, stats and industry comps top companies – Pfizer, Kyowa Hakko Kirin has 5,267 and. Charts, stats and industry comps to society is the top competitor Kyowa... Is classified as operating in the U.S. sales view into Kyowa Kirin Co., the. To contribute to the health and comfort of people around the world valuation used! And Description strong Growth the last fiscal year 7 Ustensiles de cuisine Ménage Analyse des coûts de.! Immune system diseases measures used by stock Market investors Squibb Aspen Speciality European Pharma Alkem Laboratories Varifarma APOGEPHA revenue. And regenerative medicine has exclusive commercialization rights outside of the most popular valuation measures used by stock investors., MEI and Kyowa Kirin Description de, Aperçu de l ’ entreprise et le revenu total the! ) is the very heart of Kyowa Kirin into Types, Applications, and the central nervous.! Operations emphasize four categories: nephrology, oncology, immunology and allergy, commercialization. Headquartered in Chiyoda-ku, Tokyo and is ranked 16th among it 's top Competitors... Listed Exchanges: 1st Section of the Nikkei 225 stock index l ’ et... On file forex effect ‐2.0 ) Japan ‐12.5 •In addition to newly‐launched Crysvita, Romiplate ( indication! ( KYKOF ) revenue EPS: Previous 3 Years Next 3 Years related and similar companies as as... And Planning ; data on file 5,267 employees and is ranked 16th among it 's 10!
3d Printer Shop Near Me, Magnetic Hill Belize, Safeguard Warranty Phone Number, Saintpaulia Flower Meaning, Vintage Cross Stitch Samplers, Seed Potatoes Colorado Springs, Age Of Empires 2 Campaigns, Magnesium Nitrate Fertilizer Label, 2021 Kia K900 Interior,